BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Menarini Group Announces Positive Phase 3 Trial Results for Obicetrapib in Lowering LDL-C

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically ...

July 30, 2024 | News

Akeso's Ivonescimab sBLA Accepted by NMPA for First-Line Treatment of PD-L1 Positive NSCLC

Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class...

July 30, 2024 | News

PolyU Researchers Discover Key Mechanism in Eye Pressure Regulation for Glaucoma Treatment

Glaucoma is one of the leading causes of visual impairment and blindness. According to statistics from the Hospital Authority, in Hong Kong, three out of e...

July 26, 2024 | News

Ractigen Therapeutics' RAG-18 Receives FDA Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, announced that the U.S. Food and Drug Administration (FDA) has ...

July 26, 2024 | News

Sirnaomics Completes IND-Enabling Studies for siRNA Therapeutic STP125G Targeting ApoC3

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”),...

July 24, 2024 | News

Duke-NUS Launches LIVE Ventures: S$20M to Commercialize Academic Research

Duke-NUS Medical School launched LIVE Ventures, a S$20 million incubation programme designed to catalyse the commercialisation of innovative acad...

July 22, 2024 | News

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

July 17, 2024 | News

Full-Life Technologies and SK Biopharmaceuticals Ink $571.5 Million Deal for Exclusive Rights to Radiopharmaceutical FL-091

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced that it has entered into a license agreement wit...

July 17, 2024 | News

Biosyngen's Groundbreaking CAR-T Therapy BRG01 Approved for Phase II Clinical Trial in China

Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation ...

July 17, 2024 | News

Sabin Vaccine Institute Launches Phase 2 Trial for Sudan Ebolavirus Vaccine in Uganda

Sabin Vaccine Institute launched a Phase 2 clinical trial for its vaccine against Sudan ebolavirus, with healthy volunteers receiving the single-...

July 16, 2024 | News

Everest Medicines Announces Positive Topline Data from Phase 3 Trial of Etrasimod for Ulcerative Colitis in Asia

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

July 16, 2024 | News

Senhwa Biosciences Submits IND to FDA for Phase I/II Trial of Silmitasertib in Pediatric Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemother...

July 15, 2024 | News

MSD Completes Acquisition of Eyebiotech Limited, Expands Late-Stage Pipeline with Promising Retinal Disease Treatment

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). ...

July 15, 2024 | News

National Cancer Center and University of Pennsylvania License CCR4 CAR-T Cell Therapy to ARC Therapies Inc.

The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a ch...

July 12, 2024 | News

Stay Connected